Melatonin functions as a cellular architect, not just a scavenger
En los laboratorios de Granada y Lyon, investigadores han descubierto que la melatonina —conocida principalmente como reguladora del sueño— desempeña un papel mucho más profundo en la arquitectura de la vida celular. Cuando la obesidad y la diabetes tipo 2 coexisten, destruyen los puentes que conectan las centrales energéticas de nuestras células; la melatonina, según este hallazgo, es capaz de reconstruirlos. Es un recordatorio de que las moléculas más familiares guardan, a veces, los secretos más transformadores.
- La obesidad y la diabetes tipo 2 juntas no solo sobrecargan el cuerpo: rompen silenciosamente los canales de comunicación dentro de cada célula, desencadenando inflamación y colapso metabólico.
- Los puentes celulares llamados MAMs —que conectan mitocondrias y retículo endoplasmático— se deterioran en estas condiciones, privando a las células de su capacidad para gestionar energía con eficiencia.
- El equipo del profesor Ahmad Agil administró melatonina de forma crónica en modelos animales y observó cómo esos puentes se reconstruían, restaurando el equilibrio del calcio, reduciendo el daño oxidativo y frenando señales de muerte celular.
- El descubrimiento reencuadra a la melatonina: ya no es solo un antioxidante, sino un arquitecto celular capaz de reorganizar la estructura interna de las células.
- El siguiente paso es trasladar estos resultados a ensayos clínicos en humanos, para saber si la hormona puede reparar en personas lo que ha demostrado restaurar en animales.
La melatonina hace más que regular el sueño. Investigadores de las universidades de Granada y Lyon han descubierto que esta hormona cumple una segunda función, oculta y decisiva, dentro de nuestras células —una que podría cambiar la forma en que entendemos y tratamos la obesidad y la diabetes tipo 2.
Cuando ambas enfermedades coinciden, algo se rompe a nivel celular. Las mitocondrias —la central eléctrica de la célula— y el retículo endoplasmático —su cadena de producción— pierden la capacidad de comunicarse. Normalmente están unidas por estructuras dinámicas llamadas MAMs, que permiten el intercambio rápido de señales y moléculas. Con la obesidad y la diabetes, esos puentes se deterioran, y el resultado es estrés oxidativo, inflamación y un fallo metabólico en cascada.
El estudio, publicado en Cell Communication and Signaling, muestra que la melatonina puede reparar esas conexiones rotas. El equipo liderado por el profesor Ahmad Agil administró la hormona de forma crónica en modelos animales de ambos sexos y observó cómo los puentes se reconstruían. La melatonina mejoró la salud mitocondrial, equilibró los niveles de calcio intracelular, redujo el daño oxidativo a lípidos críticos como la cardiolipina e impidió la liberación de citocromo c, una proteína que desencadena la muerte celular.
Lo más significativo no es solo lo que la melatonina repara, sino cómo lo hace. Más allá de su conocida acción antioxidante, actúa como arquitecta celular: reorganiza la estructura interna de las células y optimiza la cooperación entre sus componentes. Esa distinción abre posibilidades terapéuticas nuevas, orientadas no a neutralizar el daño sino a restaurar la comunicación que permite a las células funcionar como sistemas integrados.
El reto ahora es traducir estos hallazgos en animales a ensayos clínicos en humanos, para comprobar si la hormona puede producir los mismos efectos restauradores en quienes viven con estas enfermedades.
Melatonin does more than help you sleep. Researchers at the University of Granada, working with colleagues from the University of Lyon, have discovered that the hormone performs a second, hidden job inside our cells—one that could reshape how we understand and treat obesity and type 2 diabetes.
The finding centers on a problem that occurs when these two conditions overlap. In people carrying both obesity and type 2 diabetes, something breaks down at the cellular level. Two crucial structures inside the cell—the mitochondria and the endoplasmic reticulum—lose their ability to communicate. Think of mitochondria as a cell's power plant, generating the energy needed for every function. The endoplasmic reticulum is the factory floor, manufacturing and distributing proteins and fats throughout the cell. Normally, these two structures stay connected through specialized bridges called MAMs, dynamic pathways that allow rapid exchange of signals and molecules. When obesity and diabetes develop, these bridges deteriorate. The result is oxidative stress, inflammation, and a cascade of metabolic failure.
The new research, published in the journal Cell Communication and Signaling, shows that melatonin can repair these broken connections. Working with animal models of both sexes, the Granada team led by pharmacology professor Ahmad Agil administered melatonin chronically and watched the cellular bridges rebuild themselves. The hormone restored functional communication between the two structures, recovering the cell's ability to manage energy efficiently.
What makes this discovery significant is what it reveals about melatonin's actual mechanism. Scientists have long known the hormone acts as an antioxidant—a cellular scavenger that neutralizes harmful free radicals. But this work demonstrates something deeper: melatonin functions as a cellular architect, reorganizing the internal structure of cells and optimizing how their components work together. The hormone improved mitochondrial health, balanced calcium levels inside cells, reduced oxidative damage to critical lipids like cardiolipina, and prevented the release of cytochrome c, a protein that triggers cell death.
Agil explained the implications in measured terms: the findings allow researchers to understand melatonin not merely as a neutralizer of damage, but as a modulator of cellular architecture and inter-organelle communication. That distinction opens new therapeutic possibilities. Rather than focusing solely on antioxidant effects, future treatments could harness melatonin's ability to rebuild the physical connections that allow cells to function as integrated systems.
The work represents a shift in how scientists think about metabolic disease. Obesity and type 2 diabetes are not simply problems of excess calories or insulin resistance—they are problems of cellular communication breakdown. If melatonin can restore that communication, it suggests a pathway toward treatments that address the root cause rather than just the symptoms. The next phase will be translating these animal model results into human trials, testing whether the hormone can produce the same restorative effects in people living with these conditions.
Notable Quotes
These results allow us to understand melatonin as a modulator of cellular architecture and communication between organelles, opening new therapeutic possibilities— Ahmad Agil, pharmacology professor at University of Granada
The Hearth Conversation Another angle on the story
So melatonin is just a sleep aid, right? Why would it matter for obesity and diabetes?
That's the old understanding. What this research shows is that melatonin has been doing something else in your cells all along—something that has nothing to do with sleep. It's been maintaining the communication lines between your mitochondria and your endoplasmic reticulum.
And those structures lose connection when someone develops obesity and diabetes?
Exactly. The bridges between them, called MAMs, deteriorate under metabolic stress. When that happens, the cell can't manage energy properly, oxidative damage accumulates, and the whole system starts to fail.
Can melatonin actually fix that damage once it's done?
In the animal models they tested, yes. When they gave melatonin chronically, the bridges rebuilt themselves. The cells recovered their ability to communicate and function efficiently.
Is this just another antioxidant story, or is something different happening?
It's fundamentally different. Melatonin isn't just mopping up free radicals. It's actually reorganizing the architecture of the cell itself, restoring the physical connections that allow different parts to work as one system.
What happens next? Can they test this in humans?
That's the critical question. The animal models are promising, but human trials will determine whether this cellular repair actually translates into clinical benefit for people with these diseases.